An update from Cybin ( ($TSE:CYBN) ) is now available. Cybin Inc. announced it will release its second quarter financial results and provide a ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage ...

- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining ...

Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through ...

The latest announcement is out from Cybin ( (TSE:CYBN) ).

Canaccord Genuity analyst Sumant Kulkarni has maintained their bullish stance on CYBN stock, giving a Buy rating on October 31. Sumant Kulkarni’s Buy rating for Cybin Inc. (ticker: CYBN) is based on ...

Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achieving a primary efficacy endpoint in its Phase 2 study of CYB003 for treating Major ...

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by ...